COMBAREL, David; DOUSSET, Lea; BOUCHET, Stephane; FERRER, Florent; TETU, Pauline; LEBBE, Celeste; CICCOLINI, Joseph; MEYER, Nicolas; PACI, Angelo

doi:10.1016/j.critrevonc.2024.104384

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

COMBAREL, David

DOUSSET, Lea

BOUCHET, Stephane
Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

Critical Reviews in Oncology/Hematology. 2024-07-01, vol. 199, p. 104384

Résumé en anglais

A multitude of TKI has been developed and approved targeting various oncogenetic alterations. While these have provided improvements in efficacy compared with conventional chemotherapies, resistance to targeted therapies occurs. Mutations in the kinase domain result in the inability of TKI to inactivate the protein kinase. Also, gene amplification, increased protein expression and downstream activation or bypassing of signalling pathways are commonly reported mechanisms of resistance. Improved understanding of mechanisms involved in TKI resistance has resulted in the development of new generations of targeted agents. In a race against time, the search for new, more potent and efficient drugs, and/or combinations of drugs, remains necessary as new resistance mechanisms to the latest generation of TKI emerge. This review examines the various generations of TKI approved to date and their common mechanisms of resistance, focusing on TKI targeting BCR-ABL, epidermal growth factor receptor, anaplastic lymphoma kinase and BRAF/MEK tyrosine kinases.< Réduire

Mots clés en anglais

BRAF

Melanoma

Pharmacodynamic

Pharmacokinetic

Tyrosine kinase inhibitors

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche